Currency effects mask underlying growth at Astellas
This article was originally published in Scrip
Astellas's sales and profits were hit by the strong yen and costs related to acquisitions in the nine months to December 31st, like many of its peers. Total net sales fell by 1% to ¥758.9 billion ($8.5 billion), with exchange rate effects knocking some ¥40.9 billion off the topline.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.